Umeclidinium/vilanterol - GlaxoSmithKline/Innoviva

Drug Profile

Umeclidinium/vilanterol - GlaxoSmithKline/Innoviva

Alternative Names: '444+'719; '719/VI; 573719/642444; 642444/573719; Anoro Ellipta; GSK 573719/GW 642444; Laventair; UMEC/VI; Vilanterol/GSK 573719; Vilanterol/umeclidinium

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline
  • Class Antiasthmatics; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethanolamines; Ethers; Phenols; Quinuclidines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Jul 2016 GlaxoSmithKline does not wish to exercise the option to take a licence to any additional patents and option agreement for Ellipta® products under the worldwide non-exclusive agreement with Vectura
  • 18 May 2016 Efficacy data from a phase III trial (DB2116960) in Chronic obstructive pulmonary disease released by GlaxoSmithKline
  • 08 Jan 2016 Theravance is now called Innoviva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top